Influence of intravesical administration of tumor necrosis factor alpha and systemic gamma-interferon on murine bladder cancer: lack of dose response.
The effect of intravesical administration of high dose recombinant tumor necrosis factor-alpha (rTNF) and in combination with systemic recombinant gamma-interferon (rIFN) on murine bladder cancer was studied. RTNF was given at 12.5 micrograms/mouse on days 7, 11 and 15 after tumor instillation or at 2.5 micrograms/mouse on days 7, 9, 11, 13 and 15. Some groups were also injected i.v., 24-h prior to each rTNF treatment with rIFN at a dose of 1.3 micrograms/mouse. RTNF treatment suppressed tumor growth up to 48% of control, although the difference was not statistically significant. Combined administration of rIFN did not provide additional benefit.
Lee
K
K
University of Rochester School of Medicine, New York.
O'Donnell
R W
RW
Cockett
A T
AT
D000283:Administration, Intravesical; D000818:Animals; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma